[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cybin Inc (CYBN.NE)

Cybin Inc (CYBN.NE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [Cboe CA]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cybin Inc 100 King Street West Suite 5600 Toronto ON M5X 1C9 CAN

P: 908-764-8385

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

Key Statistics

Overview:

Market Capitalization, $K 554,429
Shares Outstanding, K 49,894
% of Institutional Shareholders 0.24%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -79,055 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -33,722 K

Growth:

1-Year Return -14.22%
3-Year Return -42.50%
5-Year Return -84.69%

Per-Share Information:

Most Recent Earnings -1.39 on 11/13/25
Next Earnings Date N/A
Earnings Per Share ttm -3.77
Dividend Payout Ratio 0.00%
Most Recent Split 1-38 on 09/19/24

CYBN.NE Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -51.64%
Return-on-Assets % -45.08%
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Book 2.91
Book Value/Share 3.82
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.